Context Therapeutics (NASDAQ:CNTX) Rating Reiterated by HC Wainwright

Context Therapeutics (NASDAQ:CNTX)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a research report issued to clients and investors on Monday, Benzinga reports. They presently have a $6.00 target price on the stock. HC Wainwright’s price target would suggest a potential upside of 188.46% from the stock’s current price.

Context Therapeutics Stock Performance

CNTX stock opened at $2.08 on Monday. Context Therapeutics has a one year low of $0.77 and a one year high of $2.75. The firm has a market cap of $156.00 million, a PE ratio of -1.56 and a beta of 2.31. The firm’s 50 day moving average price is $2.31 and its 200-day moving average price is $1.86.

Context Therapeutics (NASDAQ:CNTX) last posted its earnings results on Wednesday, August 7th. The company reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.04. Equities research analysts predict that Context Therapeutics will post -0.31 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. Renaissance Technologies LLC raised its stake in shares of Context Therapeutics by 63.4% in the 2nd quarter. Renaissance Technologies LLC now owns 65,200 shares of the company’s stock valued at $131,000 after acquiring an additional 25,300 shares during the period. Opaleye Management Inc. raised its position in Context Therapeutics by 13.7% in the first quarter. Opaleye Management Inc. now owns 1,108,357 shares of the company’s stock valued at $1,530,000 after purchasing an additional 133,357 shares during the period. Ally Bridge Group NY LLC lifted its stake in Context Therapeutics by 159.8% during the second quarter. Ally Bridge Group NY LLC now owns 1,886,232 shares of the company’s stock worth $3,782,000 after purchasing an additional 1,160,281 shares in the last quarter. Affinity Asset Advisors LLC boosted its position in shares of Context Therapeutics by 392.4% during the second quarter. Affinity Asset Advisors LLC now owns 1,619,140 shares of the company’s stock worth $3,246,000 after buying an additional 1,290,323 shares during the period. Finally, Nantahala Capital Management LLC acquired a new stake in shares of Context Therapeutics in the second quarter valued at $3,881,000. Hedge funds and other institutional investors own 14.03% of the company’s stock.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.